Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$4.25 USD
-0.11 (-2.52%)
Updated Oct 13, 2025 04:00 PM ET
After-Market: $4.24 -0.01 (-0.24%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LRMR 4.25 -0.11(-2.52%)
Will LRMR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for LRMR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LRMR
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
LRMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Other News for LRMR
Is LRMR signaling selling opportunity? Fell Below 20 Day Moving Average shows up after slipping 4.18%
LRMR forms NR7 on October 9
Calm After Storm appears for LRMR after 2.12% move
Calm After Storm appears for LRMR after 1.87% move
Truist Financial Sticks to Its Buy Rating for Larimar Therapeutics (LRMR)